<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00915369</url>
  </required_header>
  <id_info>
    <org_study_id>DO/NDR/02/2008/01</org_study_id>
    <nct_id>NCT00915369</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Study the Effects of Nanoparticle Based Paclitaxel Drug, Which Does Not Contain the Solvent Cremophor, in Advanced Breast Cancer</brief_title>
  <official_title>A Multicentre Phase I Study Of Cremophor FreePaclitaxel Nanoparticle In Advanced Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fresenius Kabi Oncology Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fresenius Kabi Oncology Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multicentre, open label, non-randomized phase I study. The main objectives of
      the study are to determine the pharmacokinetic profile of the drug at different dose levels
      in the patients with Advanced Breast Cancer. Maximum Tolerated Dose (MTD) and safety of
      Paclitaxel Nanoparticle will also be simultaneously assessed.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2009</start_date>
  <completion_date type="Anticipated">April 2010</completion_date>
  <primary_completion_date type="Anticipated">April 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcomes of the study would be the Pharmacokinetic data at all the four dose levels (220, 260, 310 and 375 mg/m2); Ability to identify a dose higher than 220 mg/m2 that demonstrate better efficacy and manageable toxicity</measure>
    <time_frame>Throughout the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>evaluation of the effect of Paclitaxel Nanoparticle formulation on QTc.</measure>
    <time_frame>Throughout the study</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Advanced Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nanoxel (Paclitaxel Nanoparticle formulation )</intervention_name>
    <description>Nanoxel (Nanoparticle Paclitaxel) at 4 different dose levels of 220, 260, 310 and 375 mg/m2. Each patient will recieve upto 6 cycles.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patients with histopathologically /cytologically confirmed advanced breast
             cancer, refractory / recurrent* to previous anthracycline treatment as adjuvant or
             first line therapy for metastasis.

          -  Patients with ER/PR -ve or ER/PR receptor status unknown (defined as no
             histopathological evidence for confirmation of ER/PR status)

          -  Patients must be of 18-65 years of age (inclusive of both)

          -  Patients with ECOG performance status between 0 - 2

          -  Patients with at least one measurable lesion as per RECIST

        Exclusion Criteria:

          -  Patients with ER/PR positive status. Patients who demonstrate HER2 over expression
             will be excluded. Alternatively, the patients enrolled should have previously received
             trastuzumab. HER2 over expression should be demonstrated by IHC 3+, IHC 2+ or with
             FISH/CIS.

          -  Patients with known history of hypersensitivity to paclitaxel or any other taxane or
             compounds chemically / biologically related to paclitaxel or excipients.

          -  Patients requiring any concurrent chemotherapy, hormonal therapy immunotherapy,
             therapy with biologicals or radiotherapy for the disease. (Patients requiring local
             radiotherapy for non- target bone lesion will be included).

          -  Patients with known CNS lesions (brain metastasis or carcinomatous meningitis).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shivakant Mishra, PhD</last_name>
    <phone>+91.120.4378604</phone>
    <email>shivakant.mishra@fresenius-kabi.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amit Sharma, MD</last_name>
    <phone>+91.120.4378415</phone>
    <email>amit_delhi.sharma@fresenius-kabi.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nizam'S Institute of Medical Sciences</name>
      <address>
        <city>Hyderabaad</city>
        <state>Andhra Pradesh</state>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>D. Raghunadharao, DM</last_name>
      <phone>+91.40.23372947</phone>
      <email>draghu_hyd@dataone.in</email>
    </contact>
    <investigator>
      <last_name>D Raghunadharao, DM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kidwai Memorial Institute of Oncology</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Govind Babu</last_name>
      <phone>+91.80.26579503</phone>
      <email>kgbtrials@yahoo.co.in</email>
    </contact>
    <investigator>
      <last_name>Govind Babu, DM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SEAROC Cancer Center, S K Soni Hospital</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anish Maru, DM</last_name>
      <phone>+91-0141-2232409-11</phone>
      <phone_ext>106</phone_ext>
      <email>anishmaru@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Anish Maru, DM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2009</study_first_submitted>
  <study_first_submitted_qc>June 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2009</study_first_posted>
  <last_update_submitted>February 5, 2010</last_update_submitted>
  <last_update_submitted_qc>February 5, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr. S. K. Mishra, Vice President - Clinical Research &amp; Medical Services</name_title>
    <organization>Fresenius Kabi Oncology Ltd.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

